Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Sued By Ex-Employee For Innovation That Led To Vitamin Line

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals is being sued by a 73-year-old former researcher for nearly $541,000, saying the $433 the firm paid him for his role in developing a vitamin B1 derivative was not enough. The man's discovery of an efficient way to obtain a key substance from the B1 vitamin derivative, fursultiamine, led to Takeda's highly successful line of Alinamin products. Takeda reported nearly $6 billion in sales from the Alinamin product line. The man received an additional $162 after 1998 and the firm's new program of compensation for on-the-job inventions. Takeda said it has fulfilled its obligations to the researcher. (Click here for more - a subscription may be required

You may also be interested in...

Teligent Moves To Consolidate Shares To Stay Listed

Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts